Clearview Cancer Institute - Clinical Trials

Quick Links:

Events & Groups:

Clinical Trials

Did you know Clearview Cancer Institute has been involved in Clinical Research for over 18 years? Findings from clinical trial research have led to significant advances in cancer prevention and treatment, and Clearview offers numerous clinical trials whereby patients who volunteer for them receive innovative, state-of-the-art cancer care.

Colorectal Cancer

DEBIRI -- Drug Eluting Bead, Irinotecan (DEBIRI) therapy of liver metastasis from colon cancer with concomitant systemic Oxaliplatin, Flourouracil and Leocovorin chemotherapy and Anti- angiogenic therapy

Rationale:

Colon cancer is the second most common cancer in developed countries. At the time of diagnosis approximately 25% of patient will present with metastasis to the liver. In patients with metastases confined to the liver, surgical resection or complete tumor ablation provides the only treatment able to offer long term survival. In most patients, liver metastases prove to be unresectable, therefore chemotherapy using FOLFOX regimen is the standard treatment for advanced colon cancer. In recent years, the introduction of trans-arterial chemotherapy embolization (TACE) has been investigated in the treatment of hepatic lesions. The rationale for hepatic arterial chemotherapy comes from the fact that most hepatic lesions are hypervascularized and the administration of chemotherapy directly into the liver provides effective tumor responses.

Purpose:

This is a randomized study evaluating the use of chemotherapy (FOLFOX) and Avastin (MD choice) with or without hepatic arterial chemotherapy embolization (TACE). The primary objective of this study is to compare the response of chemotherapy alone with chemotherapy and the addition of TACE. Other purposes of the study include finding out more about the side effects of TACE in combination with chemotherapy.

Eligibility:

Must have at least one measurable lesion in the liver originating from colon cancer

Performance status of 0-2

Must have liver dominant disease

Adequate lab values

Patients with new diagnosis of Stage IV colorectal cancer

Patients at least one moth out from any treatment for Stage III colorectal cancer

Patients that are at least one year out from any treatment for Stage IV colorectal cancer

Patients eligible for curative treatment with resection or ablation, are not eligible

Patients allergic to contract are not eligible

Treatment:

Arm A - FOLFOX +/- Avastin in combination with Trans-arterial chemotherapy embolization (TACE)

Arm B – FOLFOX +/- Avastin

Contact:

Kathy Cutter, RN, BSN 256-705-4248

Current Clinical Trials:

Emily Pauli, Pharm.D.Director of Research

If you are interested in more information on clinical trials at Clearview, please feel free to contact us (256) 705-4224. More information regarding clinical trials can be found at: www.ClinicalTrials.gov

Entering a Clinical Trial: Is it right for you? Download the PDF.